In vitro comparison of CD20xCD3 bispecific antibodies against diffuse large B‐cell lymphoma ( DLBCL ) cell lines with different levels of expression of CD20

Documenti analoghi

• A CD38 / CD3xCD28 trispecific T‐cell engager as a potentially active agent in multiple myeloma patients relapsed and/or refractory to anti‐ CD38 monoclonal antibodies
  di: Aintzane Zabaleta, et al.
  Pubblicazione: (2024)
• Peripheral T‐cell lymphomas expressing CD30 and CD15 expand the spectrum of anaplastic large cell lymphoma, ALK‐negative
  di: Karthik A. Ganapathi, et al.
  Pubblicazione: (2024)
• Plasmacytic markers as immunotherapeutic targets for primary CD20 ‐negative aggressive B‐cell lymphomas
  di: Frank Neumann, et al.
  Pubblicazione: (2026)
• Risk of infections with bispecific antibodies in B‐cell non‐Hodgkin lymphomas and multiple myeloma—The current state
  di: Amrit S. Gonugunta, et al.
  Pubblicazione: (2024)
• Bispecific antibody combination therapies in diffuse large B‐cell lymphoma
  di: Sean Harrop, et al.
  Pubblicazione: (2025)